A Team Dedicated to Driving Innovation in Sepsis Care.
The Immunexpress Team
Pioneering Rapid Sepsis Detection
Founded in Australia, Immunexpress is dedicated to the development and commercialization of SeptiCyte® technology. As a privately-owned company, we operate from our offices in Seattle, USA, and Brisbane, Australia. Our products leverage patented host immune response technologies, validated through extensive human clinical trials worldwide, to deliver actionable results swiftly and accurately.
Our Mission
To revolutionize sepsis diagnostics by equipping clinicians with cutting-edge technology that rapidly and confidently supports accurate treatment decisions.
Executive Team
Strategic Leadership
Our Executive Team are leaders in biotechnology, clinical medicine, and regulatory affairs, working together to deliver rapid, accurate, and actionable diagnostic results.
Rolland Carlson
CEO – BA, MS, PhD
Over 25 years’ experience – business and new product development, global commercial and general management in biotechnology. President and CEO of WaferGen Biosystems; President and CEO of Asuragen Inc., a molecular diagnostic company. Vice President for Abbott Laboratories Inc., responsible for business development and licensing. Vice President and General Manager in Molecular Diagnostic Business for Vysis Inc.
Roy Davis
Chief Medical Officer – MD, PhD, MHA
30 years’ experience in clinical medicine (Neonatal, Pediatric Critical Care) and hospital administration. Clinical Asst. Prof., Dept. of Pediatrics, University of Washington. Consultant in health care standards and quality of care delivered. CMO, Providence Alaska assisted in the implementation of MEWS and sepsis surveillance algorithms across their network. Won a national Microsoft Healthcare innovation award for work with MEWS in 2012.
Jane Papadaki Markley
Vice President, Market Development and Commercial Operations
With 30 years’ experience in the global clinical diagnostics and biotech markets, Jane has held commercial leadership roles at Quest Diagnostics, Qiagen, Asuragen, and Takara Bio. She pioneered new technologies for infectious disease, immunology, oncology, and genetic diseases, overcoming market entry barriers and setting new standards for clinical diagnosis in Lyme borreliosis, C. pneumoniae, BCR/ABL, and Fragile X.
Richard Brandon
Chief Scientific Officer – BVSc (Hons), PhD, MBA
35 years’ experience – veterinary immunologist, molecular biologist, pathologist, animal and human healthcare R&D executive: Cornell, Sloan Kettering Cancer Research, University of Queensland, various private pathology laboratories, Genetrax, Plasvacc, BioNiche. A listed inventor on most Immunexpress patents; architect of IP strategy.
Silvia Cermelli
Director of Clinical Operations – PhD (Cell Biology)
20 years’ experience – cell/molecular biologist, clinical research and product development mgmt., biomarker discovery & validation, targeted cancer therapy identification – Principal Scientist/Advisor (Cell System Corp), Postdoctoral Fellow (Fred Hutchinson CRC). PhD in cell biology from UC Irvine. ACRP-certified Clinical Professional. Current Board of Directors member of BioPharma PM.
LaKesha Hunt-Dickens
Director, Quality & Regulatory Affairs -- MBA, MS
15 years’ experience – medical device, diagnostics, pharmaceuticals, biotechnology, and defense. Compliance, Quality Management Systems, regulatory affairs, risk management, and business process improvement experience at ThermoFisher Scientific and BioVeris. MBA and a MS in Biotechnology from the University of Maryland UC.
Krupa Navalkar
Director, Bioinformatics – PhD in Biological Design
20 years experience in developing, testing & validating infectious disease diagnostics in hospital systems. Her prior training is in Microbiology, Pathology and Bioinformatics.
She developed diagnostics to detect exposure to priority pathogens using peptide microarrays through the Immunosignature technology at Arizona State University.
Greg Uhl
Director, Finance - BS (Accounting), MPAcc (Audit and Assurance)
15 years’ experience – corporate finance, accounting and assurance. Oversight over GAAP reporting, development of technical accounting policies and ICFR. Financial Controller (Immunexpress); Controller (GroupAero), Audit Manager (PricewaterhouseCoopers, RSM). Masters of Professional Accounting – University of Washington.
Thomas Yager
Sr. Director of Research & Development – BA, MS, PhD
30 years’ experience. University of Oregon, Weizmann Institute, Kings College London, Hospital for Sick Children (Toronto), and cross-appointment to Dept. Molecular/Medical Genetics, University of Toronto. Broad industry experience in biomarker discovery, development & validation of molecular diagnostic assays; multiple regulatory submissions in USA, Canada and Europe.
Prashant Wani
Sr. Technical Product Manager - PhD in Biochemistry
12 years of experience in biochemistry and molecular biology research and assay development. Managed and commercialized several molecular and sequencing-based assays and cell analysis instruments at biotech companies like Takara Bio, Bio-Rad, and Twist Bioscience. Expertise in customer relationship management and building B2B relationships.
Our Board of Directors
Experience and Expertise
Our esteemed Board of Directors brings a wealth of experience and expertise, guiding Immunexpress towards innovation and excellence in sepsis diagnostics.
Robert Lilley
Chairman – BA (Yale)
40 years’ experience - SVP, Global Sales & Marketing for Digene Corp from IPO to acquisition by QIAGEN NV (in 2007) creating market & technology leader in molecular Dx. Then, Senior Advisor/Molecular Diagnostics for Developing World at QIAGEN. Consultant to John D Rockefeller 3rd Fund, 23andMe, ImpediMed Pty Ltd, Vertex Pharma, OpGen.
Rolland Carlson
CEO – BA, MS, PhD
Over 25 years’ experience – business and new product development, global commercial and general management in biotechnology. President and CEO of WaferGen Biosystems; President and CEO of Asuragen Inc., a molecular diagnostic company. Vice President for Abbott Laboratories Inc., responsible for business development and licensing. Vice President and General Manager in Molecular Diagnostic Business for Vysis Inc.
Katleen Verleysen
Non-Executive Director – MSc, PhD
Dr. Katleen Verleysen joined miDiagnostics as CEO in May 2021, bringing over 20 years of experience in the Life Sciences sector. She has served as CEO at Pronota, CellSeeQ, and DNameIT, and holds board positions at ImmunExpress, PharmaFluidics, and the Center for Medical Innovation. Dr. Verleysen holds a Ph.D. in Analytical Chemistry from the University of Ghent and completed a postdoctoral fellowship at Duke University.
Tom Gibb
Non-Executive Director – BSc, PhD
30 years’ international experience with responsibility for operations, marketing, business development and investment in both start-ups and established life science companies, including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm. Presently Director at Debiopharm Innovation Fund, Switzerland. Current and recent board experience includes BC Platforms, Kaiku Health, Biocartis, GenePOC.
Brian Flannery
Non-Executive Director
40+ years’ global experience as a mining engineer. Recently Brian has focused on growing his own family office with interests spanning resources, energy, property development and philanthropy. He holds directorships in several related companies and is Managing Director of ASX listed White Energy Company Limited. Brian has also been Chairman of the Mater Foundation and led several other major ASX listed companies.
In the News
Here, you'll find breakthrough developments, expert commentary, and real-world impacts of our advanced diagnostic technologies. Stay informed with our regular updates as we continue to transform the landscape of sepsis diagnosis and patient care.
From Lab to Launch podcast from Qualio
Hear Dr. Rolland Carlson, CEO of Immunexpress talk about the transformative work happening in sepsis diagnosis.
Dr. Carlson discusses the importance of rapid sepsis diagnosis. The episode covers challenges faced during product development, regulatory achievements, and future plans for sepsis diagnostics. Dr. Carlson also shares advice on ensuring product quality and navigating FDA clearances.